CAM
ADPT icon

ClariVest Asset Management’s Adaptive Biotechnologies ADPT Stock Holding History

ClariVest Asset Management’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-176
Closed -$1K – 869
2023
Q3 		$1K Sell
176
-117
-40% -$774 ﹤0.01% 551
2023
Q2 		$2K Buy
293
+67
+30% +$498 ﹤0.01% 488
2023
Q1 		$2K Buy
226
+109
+93% +$961 ﹤0.01% 543
2022
Q4 		$1K Buy
+117
New +$910 ﹤0.01% 582

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
AAP
Aristotle Atlantic Partners Sarasota, Florida $2.14B AUM 37.01% 1-Year Est. Return

ClariVest Asset Management's ADPT Position: Q4 2023 in Review

ClariVest Asset Management sold out of Adaptive Biotechnologies (ADPT) in Q4 2023, closing a stake of 176 shares — an estimated $1K sold.

ClariVest Asset Management first reported a position in ADPT in Q4 2022 and held it in 4 quarters. The position peaked at $2K in Q2 2023. 200 funds tracked by Wall St. Rank hold ADPT as of Q4 2023.

  • ClariVest Asset Management reported no remaining Adaptive Biotechnologies position as of Q4 2023 after selling out during the quarter.
  • ClariVest Asset Management sold 176 Adaptive Biotechnologies shares in Q4 2023, an estimated $1K.
  • ClariVest Asset Management first reported a position in Adaptive Biotechnologies in Q4 2022 and held it in 4 quarters.
  • ClariVest Asset Management's Adaptive Biotechnologies position peaked at $2K in Q2 2023.
  • 200 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q4 2023.

Based on ClariVest Asset Management's 13F filing for Q4 2023, filed 13 Feb 2024.